Engineers Gate Manager LP Cyma Bay Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $586,244 - $951,162	53,982 New	53,982 $804,000
Q3 2021 Nov 15, 2021	SELL	$3.47 - $4.42 $38,131 - $48,571	-10,989 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.94 - $4.92 $1,166 - $1,456	296 Added 2.77%	10,989 $48,000
Q1 2021 May 17, 2021	BUY	$4.23 - $6.55 $45,231 - $70,039	10,693 New	10,693 $49,000
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $198,907 - $433,762	-59,912 Closed	0 $0

Q2 2020 Aug 17, 2020	BUY	$1.41 - $4.25 $59,556 - $179,515	42,239 Added 239.0%	59,912 $209,000
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $87,358 - $141,171	-69,887 Reduced 79.82%	17,673 $26,000
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $63,929 - $285,037	48,067 Added 121.71%	87,560 $172,000
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $883,952 - $1.24 Million	-172,647 Reduced 81.38%	39,493 $202,000
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $728,946 - $1.65 Million	120,487 Added 131.46%	212,140 $1.52 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $258,786 - $425,601	31,714 Added 52.91%	91,653 $1.22 Million
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $392,001 - $703,683	59,939 New	59,939 $472,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.